Regeneron Pharmaceuticals, Inc.

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 7, 2025), Regeneron Pharmaceuticals, Inc. reported 4 stock positions worth $700.4 million. Its top holding was Alnylam Pharmaceuticals (ALNY) at 90.6% of the portfolio, followed by Intellia Therapeutics (NTLA, 9.1%) and Adverum Biotechnologies (ADVM, 0.1%). Compared with Q2 2025, it reduced 1. The biggest sale was Alnylam Pharmaceuticals (ALNY, shares −69%).

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$700.4M (Q3 2025)
SEC Filing
0001104659-25-108546 ↗ filed Nov 7, 2025

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B Q2 2025 Q3 2025: $700.4M $700.4M Q3 2025 Q4 2025: $33.8M Q4 2025 Q1 2026: $47.9M Q1 2026 Q2 2026: $177.2M Q2 2026

Holdings 4 stocks · $700.4M
ALNY Alnylam Pharmaceuticals Inc. 90.64% 1,392,303 $634.9M Reduce -68.7%
NTLA Intellia Therapeutics Inc. 9.13% 3,702,995 $64.0M No change
ADVM Adverum Biotechnologies Inc. 0.12% 180,909 $820K No change
ACET Adicet Bio Inc. 0.11% 968,183 $784K No change

Portfolio Sells Q2 2025 → Q3 2025
ALNY Alnylam Pharmaceuticals Inc. Reduce -68.7% 90.64% −6.95

Portfolio Buys Q2 2025 → Q3 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM